Although breast carcinoma has many targeted biomarkers for its treatment, it needs new markers especially for the triple-negative group. Androgen receptor (AR) has been known as an important contributor in breast carcinogenesis, and its frequency makes it a promising therapeutic target. The aim of this study was to detect the prevalence of AR expression in invasive duct carcinoma, as well as its relation to breast carcinoma subtypes and outcome.Materials and methods
A total of 111 cases of invasive duct carcinoma were included and analyzed immunohistochemically for AR expression. Correlation of AR expression with histopathological factors, breast cancer subtypes, and 2-year disease-free survival was explored.Results
AR was expressed in 72.1% of cases. It was significantly associated with breast cancer subtypes (P=0.001). AR was detected in 82.9% of hormone receptor-positive cases, in 68.8% of human epidermal growth factor receptor 2-positive cases, and in 44% of triple-negative breast cancer cases. AR-positive breast cancer cases had better prognosis than those with AR-negative breast cancer (80 vs. 67.7%).Conclusion
Our results emphasized the role of AR in breast cancer and its association with breast cancer subtypes. Multifaceted treatment is more promising for cure; hence, it is necessary to develop as many targets for therapy as possible, and AR appeared to be an eventual promising target for therapy with particular value in each breast cancer subtype.